ExpreS2ion Biotech Holding
ExpreS2ion Biotech (One-pager): Market value below cash balance (HC Andersen Capital via Inderes)
2024-12-23 17:09
Investment case Although not a one-product company, the huge shareholder value creation lies in the progression of its ES2B-C001 breast cancer vaccine candidate, given its unmet need within HER2+ breast cancer therapy, and very large addressable market at around USD 10bn[1] annually based on current treatments. The ES2B-C001 vaccine targets the HER2+ protein, associated with a more aggressive, higher recurrence, and higher mortality rate disease. The ES2B-C001 vaccine targets multiple HER2+ epitope sites vs existing therapies (1-2 epitopes) of the HER2-ECD. Existing monoclonal therapies have been associated with resistance, (which pre-clinical data has overcome), and additional adverse cardiac effects. An elongation of progression free survival (PFS) or reduced cardiac effects would offer a significant advantage. Disclaimer: HC Andersen Capital receives payment from the ExpreS2ion Biotech for a Digital IR/Corporate Visibility subscription agreement. Analyst Claus Thestrup 5:05 PM, 23.12.2024
info@inderes.fi (inderes.fi)
© Inderes Oyj. All rights reserved.